Key result
Dalteparin reduced the risk of venous thromboembolism across all subgroups of acutely ill hospitalized medical patients, including those with congestive heart failure.
Why the study?
Does subcutaneous dalteparin reduce the composite of symptomatic DVT, pulmonary embolism, asymptomatic proximal DVT, or sudden death in acutely ill hospitalized medical patients?
RCT (n=3,706)
Does subcutaneous dalteparin reduce the composite of symptomatic DVT, pulmonary embolism, asymptomatic proximal DVT, or sudden death in acutely ill hospitalized medical patients?
Thromboprophylaxis with dalteparin provides consistent benefits across various subgroups of acutely ill hospitalized medical patients, supporting its broad application.
Answers are grounded in this paper and cite their sources.
Dalteparin was associated with lower VTE risk across subgroups; extends observational data but should not change practice without RCTs.
It is unclear whether thromboprophylaxis produces a consistent risk reduction in different subgroups of medical patients at risk from venous thromboembolism. We performed a retrospective, post hoc analysis of 3706 patients enrolled in the PREVENT study. Patients were at least 40 years old with an acute medical condition requiring hospitalization for at least 4 days and had no more than 3 days of immobilization prior to enrolment. Patients received either subcutaneous dalteparin (5000 IU) or placebo once daily. The primary end point was the composite of symptomatic deep vein thrombosis (DVT), pulmonary embolism, asymptomatic proximal DVT, or sudden death. Primary diagnosis subgroups were acute congestive heart failure, acute respiratory failure, infectious disease, rheumatological disorders, or inflammatory bowel disease. All patients, except those with congestive heart or respiratory failure, had at least one additional risk factor for venous thromboembolism. A risk reduction was shown in patients receiving dalteparin versus placebo. The relative risk (RR) was 0.73 in patients with congestive heart failure, 0.72 for respiratory failure, 0.46 for infectious disease, and 0.97 for rheumatological disorders. The RR was 0.52 in patients aged > or = 75 years, 0.64 in obese patients, 0.34 for patients with varicose veins, and 0.71 in patients with chronic heart failure. No subgroup had a significantly different response from any other. Importantly, multivariate analysis showed that all patient groups benefited from thromboprophylaxis with dalteparin. Our findings, therefore, support the broad application of thromboprophylaxis in acutely ill hospitalized medical patients.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2007) conducted an RCT in acute medical condition requiring hospitalization (n=3,706). Dalteparin vs. Placebo was evaluated on composite of symptomatic deep vein thrombosis (DVT), pulmonary embolism, asymptomatic proximal DVT, or sudden death. Dalteparin reduced the risk of venous thromboembolism across all subgroups of acutely ill hospitalized medical patients, including those with congestive heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: